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A B S T R A C T
Multidrug-resistant tuberculosis (MDR-TB) is on the rise, and is difﬁcult to treat. The approval of two
new drugs, bedaquiline and delamanid, and growing evidence for the use of linezolid, offer renewed
hope for addressing MDR-TB. However, access to these medicines remains a signiﬁcant challenge. These
drugs have not been registered for TB in most settings; barriers to preapproval access persist; and high
pricing and intellectual property restrictions limit access. Many unanswered research questions about
optimal use of these drugs also limit access, particularly for vulnerable populations. This review outlines
challenges in accessing drugs encountered from the perspective of clinicians, patients and affected
communities, and offers potential solutions.
 2014 The Authors. Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-
nc-nd/3.0/).
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jou r nal h o mep ag e: w ww .e lsev ier . co m / loc ate / i j id1. Introduction
Drug-resistant tuberculosis (TB) is common, and the extent of
resistance rising, rendering cure and the interruption of transmis-
sion increasingly difﬁcult.1 Two new drugs, bedaquiline and
delamanid, recently received conditional regulatory approval to
treat multidrug-resistant (MDR) TB.2,3 Mounting evidence also
supports the repurposing of antibiotics, such as linezolid—
approved for other indications—for MDR-TB.4 These drugs offer
renewed hope of curing those with MDR-TB and of achieving a
world free of TB.5 Access to these medications, however, remains a* Corresponding author.
E-mail address: erica.lessem@treatmentactiongroup.org (E. Lessem).
http://dx.doi.org/10.1016/j.ijid.2014.12.012
1201-9712/ 2014 The Authors. Published by Elsevier Ltd on behalf of International So
license (http://creativecommons.org/licenses/by-nc-nd/3.0/).signiﬁcant challenge. This article highlights some of these
regulatory, ﬁnancial, and scientiﬁc access challenges from the
perspectives of patients, providers and programs, with a hope that
understanding these barriers will help overcome them.
2. Pre-approval access barriers
Pre-approval access programs, including ‘‘compassionate use’’
(CU) and ‘‘expanded access’’ programs, allow patients with limited
therapeutic options to access potentially lifesaving investigational
drugs prior to formal regulatory approval.6
Janssen, the manufacturer of bedaquiline, initiated a pre-
approval access program for bedaquiline in 2011, while the drug
was in phase IIb trials. To date, Janssen has successfully provided
nearly 500 patients with access to bedaquiline.ciety for Infectious Diseases. This is an open access article under the CC BY-NC-ND
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in the United States were complicated by a lack of clearly deﬁned
mechanisms both for dealing with requests and providing the drug.
A physician caring for a patient with extensively drug-resistant
(XDR) TB applied for CU access to bedaquiline. Various delays,
including the drug being held at U.S. customs, caused two months to
pass before bedaquiline reached the patient. The delay was a
signiﬁcant barrier in drug access, and similar delays have been
reported elsewhere. Later requests were fulﬁlled more rapidly.
Moldova, a country with a signiﬁcant MDR-TB problem, lacks a
legal framework for CU, which prevents access. Now, nearly two
years after patients, activists and a World Health Organization
(WHO) TB program review raised this issue,7 it is understood that
bedaquiline’s European Medicines Agency (EMA) approval allows
its import as ‘‘humanitarian aid’’. However, confusion over the
legality of importing bedaquiline under CU means that Moldovan
patients still have no access to bedaquiline, despite the efforts of
civil society and the Moldovan National TB Program, and Janssen’s
willingness to provide the drug.
Pre-approval access to bedaquiline initially proved challenging
for other country-speciﬁc reasons in South Africa, which has a large
MDR-TB burden, with 15,419 cases reported in 2012 alone.8
As one clinician diagnosed with MDR-TB in 2010 in South Africa
noted: ‘‘I was immediately concerned about survival, as I knew
the dismal cure rates globally—48% in 2012.9 I heard of a new
drug, bedaquiline, undergoing studies in South Africa and tried
to gain access through a recently opened CU program. I was told
I was not ill enough, as I did not have XDR-TB, despite the fact
that the drug had only been studied in patients like me with
MDR-TB.
After two months, I started losing my hearing from amikacin
therapy. I was forced to choose between my hearing (and
effectively, my career) and cure. I was extremely fortunate to
gain access to bedaquiline after re-applying, so I could stop the
amikacin therapy. I fully comprehended the risk of cardiac
arrest associated with this, but facing MDR-TB, I was willing to
take it. I was one of only four patients that gained access to the
drug before the South African Medicines Control Council closed
the CU program.’’
The South African Medicines Control Council closed this
program, citing premature data and an initial preference for a
clinical trial instead. Following the US Food and Drug Administra-
tion (FDA) approval of the use of bedaquiline to treat MDR-TB in
December 2012, and lengthy discussions with the South African
National Department of Health, the South African Medicines
Control Council ﬁnally approved in 2012 a national ‘‘Clinical Access
to Bedaquiline Programme’’, which has offered eligible patients in
approved sites access to bedaquiline under safe conditions.10
Pre-approval access to delamanid has been much more limited.
Otsuka initiated its CU program only in 2014—after EMA approval
was assured and their phase III trial had completed enrollment, and
has no expanded access. There are no clear procedures or eligibility
criteria identiﬁed to guide application for delamanid under CU. To
date, fewer than ﬁve patients have been enrolled, all of whom live
in Europe, where the drug has been approved.
A recent case has elucidated that patients treated with
bedaquiline are speciﬁcally excluded from consideration for
delamanid due to Otsuka’s concerns that both drugs may cause
modest prolongation of the QT interval; the drugs have not yet
been studied in combination.11 CU access to delamanid was denied
to a patient with the most drug-resistant TB isolate ever identiﬁed
in the United States, conﬁrmed susceptible only to linezolid and
cycloserine, and presumed susceptible to bedaquiline. This patient
had a very limited chance of survival without adding an additionaleffective drug to the regimen, and was being treated in a facility
with intensive cardiac monitoring to reduce potential risk. Due to
Otsuka’s refusal to provide delamanid, this patient is suffering
from permanent disabling side effects of a suboptimal regimen,
including hearing loss and peripheral neuropathy. Patients like this
have the most to gain from use of novel combinations of drugs, but
are speciﬁcally excluded by the company’s current policy. Notably,
in the absence of data on simultaneous use, the WHO’s recent
guidance on delamanid does not issue a negative recommendation
against its use together with bedaquiline.12 By precluding seriously
ill patients from accepting any potential risk of receiving novel
drug combinations, Otsuka’s restrictive pre-approval access policy
leaves patients with a deﬁnite risk of dying from drug-resistant TB.
This runs in stark contrast to the purpose and practice of
compassionate use, designed to offer an otherwise unavailable
treatment for the most desperate clinical cases.
A recent prospective study from South Africa showed the poor
ﬁve-year prognosis for those receiving treatment for XDR-TB: only
11% of patients with XDR-TB had a favorable treatment outcome,
and overall mortality was 73%.13 These statistics highlight the dire
and urgent need for new treatment regimens, but it will be years
before these regimens are identiﬁed and available, as deﬁnitive
research studies and new drug registration timelines are lengthy. It
is therefore crucial to make pre-approval access available to
patients now to give them a chance for survival. These access
programs also provide countries with the framework to implement
broader policy planning and roll-out of more effective MDR-and
XDR-TB regimens at a national level.
3. Registrations, normative guidance and technical assistance
barriers
Pre-approval access is critical for select urgent TB cases, but
widespread registration of new drugs is required for broad uptake.
Unfortunately, slow registration due to limited industry investment
and regulatory challenges (such as a lack of harmonization across
authorities requiring multiple onerous submission processes, and a
lack of capacity among regulators to rapidly review drug applica-
tions) has stymied access. So far, bedaquiline is only approved by six
regulatory authorities, with several more registrations in high MDR-
TB burden countries pending. Otsuka has only ﬁled for approval for
delamanid in Europe, Korea, and Japan, home to very few people
with MDR-TB; Otsuka has not registered the drug in most of the
countries where it held clinical trials.14 More registrations for both
drugs, but especially delamanid, are urgently needed.
The regulatory approval of new drugs for the treatment of TB is
just one step that must occur for medications to reach those who
need them. In most high-burden TB countries—especially those
that rely on external funding—the medication must also be
recommended by the WHO; purchased through approved mecha-
nisms and imported; and incorporated into a national plan
consistent with the overall strategy of the TB program and that
follows WHO recommendations.15,16 In addition, countries need to
develop updated clinical guidance for the use of new medications,
train implementers, and set up systems needed for the monitoring
and active pharmacovigilance that are essential parts of new drug
introduction.17–19
These steps are crucial, but can be time-consuming and prolong
the process of getting the medication to those most in need. The
WHO has developed a more streamlined process for introducing
new medications for TB under program conditions,17 but signiﬁ-
cant hurdles remain. At this writing, although several countries
have ordered bedaquiline for the treatment of MDR-TB, not a single
patient in a high-burden setting has received bedaquiline or
delamanid under program conditions. Most countries are also
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means equity in access may take years to achieve.
A new initiative, supported by UNITAID and implemented by
Partners In Health, Me´decins Sans Frontie`res and Interactive
Research and Development, is designed to jumpstart uptake of the
new drugs by overcoming some of these registration, normative
guidance and technical assistance barriers. Known as endTB, it will
spur early adoption of these drugs.20 Procuring bedaquiline and
delamanid for 3,200 patients across 20 countries over four years,
endTB will accompany programs and clinicians in the use of new
drugs. Both through an early adoption component of endTB—
delivering treatment according to current guidance—and through a
rigorous clinical trial, endTB will establish best practices in their
use. Moreover, endTB will work with local and global policymakers
to ensure that experience and evidence developed through endTB
will translate into revised policy and practice. This will end the
‘‘chicken-and-egg’’ phenomenon plaguing introduction of these
new drugs: countries are reluctant to administer them because
they are not widely used, and they are not widely used because of
insufﬁcient safety data from routine use in programs.
4. Pricing and procurement barriers
Pricing and procurement can also pose important barriers for
access to drugs for those who need them. National TB programs are
generally under-resourced, and the additive costs of new drugs can
be prohibitive. Some countries rely heavily on donor support, such
as from the Global Fund to Fight AIDS, Tuberculosis and Malaria, to
procure medicines for MDR-TB (though several high MDR-TB
burden countries are being phased out of Global Fund eligibility).21
The Global Fund has worked with some countries to reallocate
existing budgets toward the procurement of bedaquiline, for
example; however, the Global Fund will only fund procurement of
new drugs for programs meeting WHO-speciﬁed conditions.22,16
Moreover, high drug prices mean that fewer patients can be
reached with the same amount of money, and that limited funding
must be diverted away from other important areas such as
investments in health systems or procurement of essential
companion drugs. Domestic and donor funding can go much
farther when drugs are affordable.
In some cases, TB programs may simply not procure a drug due
to pricing challenges. One South African patient’s struggle to
overcome XDR-TB by taking linezolid illustrates that high drug
prices can have a devastating impact:
‘‘I was diagnosed with TB in late 2010. After about three weeks,
the doctor diagnosed me with MDR-TB. I took the MDR-TB
drugs for some time, then one morning I woke up and
everything was so quiet; I tried to turn on the television but
still there was no sound. So the next morning I told the hospital
nurse that I can’t hear, she sent me to the audio department
where the audiologist wrote down that I was deaf. Then I was
told that I now had pre-XDR-TB.
I had to take even more toxic drugs, and undergo surgery that
left me with a collapsed lung and a broken rib. Now I was at
home taking the pre-XDR-TB drugs at the clinic, only to be told
they had stopped working. Luckily enough I met a new doctor
who explained that I now had XDR-TB. She said that there was a
drug that might cure me but there was no guarantee. She also
said the drug is very expensive and it is not easily available. The
drug I was told about is linezolid.
I took linezolid with the other old drugs, and after two years it
worked and ﬁnally I was cured of XDR-TB. It was sure not aneasy journey at all, but I was lucky enough to get the drug
through Me´decins sans Frontie`res (MSF)’’.23
In South Africa, the high price (nearly USD70 per 600 mg tablet)
of brand-name linezolid limits the number of patients treated.
Now MSF has special permission to procure affordable generic
linezolid; however, widespread access is urgently needed. Had the
patient above been able to access linezolid earlier, she may not
have lost her hearing or required surgery.
Difﬁculties accessing linezolid also challenge the uptake of new
drugs, as TB drugs must be given as part of effective regimens. For
example, Romania accounts for one-third of all TB cases in the
European Union (EU) and has far more cases of MDR-TB than any
other EU member state.24 Yet linezolid, which is left off the list of
approved TB drugs and available only in brand-name form at a very
high price, is inaccessible to most. This in turn makes bedaquiline
also inaccessible: due to an inability to provide an adequate
background regimen, the vast majority of patients at the Global
Fund-supported MDR-TB treatment center in Bucharest who could
have beneﬁtted from bedaquiline under CU were never able to
access it.
Romanian doctors have expressed frustration at their inability
to treat patients with XDR-TB. According to one: ‘‘We do not treat
XDR-TB in Romania. XDR-TB patients receive the same treatment as
MDR-TB.’’ Some Romanian patients with XDR-TB have managed to
purchase linezolid, at great cost, from online pharmacies in order
to qualify for bedaquiline. However, most XDR-TB patients are
unable to do this, especially those from vulnerable groups. The
Romanian TB program’s inability to provide the necessary drugs to
form appropriate regimens represents a missed opportunity.
5. Research and development barriers
Access to new and repurposed medications is also hindered by
insufﬁcient clinical evidence guiding their optimal use, especially
in effective combinations. Delamanid and bedaquiline have each
been approved as single agents on top of a lengthy, difﬁcult to
tolerate background regimen. An understanding of how these
drugs can contribute to shorter, less toxic and more tolerable
regimens is urgently needed. Additionally, the development of and
access to rapid, reliable drug susceptibility tests to guide
appropriate treatment and monitor the development of resistance
is important to accompany new therapies.
There is a desperate need for additional drugs to treat MDR-TB.
One promising class is the oxazolidinones: sutezolid and AZD5847
are under development with the hope that they may share
linezolid’s activity against MDR-TB but have fewer adverse
events.25 But Pﬁzer transferred the rights to sutezolid, leaving
its future uncertain, with limited product available for further
studies. Similarly, AstraZeneca, maker of AZD5847, announced it
would no longer pursue TB drug development. There is clearly a
need for partnering with industry to ensure that promising agents
are fully developed.
Vulnerable populations—such as children, people with HIV, and
people who use drugs and alcohol—are routinely excluded from
research, limiting access later on. A lack of data from pharmacoki-
netic and safety studies in children to inform dosing limits pediatric
access to new TB drugs. While Otsuka’s development of delamanid
for children is advancing, Janssen’s initiation of pediatric studies of
bedaquiline has been much slower. This discordance may in part be
attributable to differing regulatory requirements: the EMA, where
Ostuka ﬁrst registered delamanid, requires a Pediatric Investiga-
tional Plan, whereas the U.S. FDA, where Janssen ﬁrst registered
bedaquiline, exempts orphan drugs—such as those for TB—from
requirements for pediatric studies.
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rates of HIV and MDR-TB can reach 70%.4 Despite this high burden,
HIV-infected MDR-TB patients are often excluded from TB drug
trials. For bedaquiline and delamanid, only 14% and 1% of
participants in the respective phase 2 clinical trials were HIV-
infected.26,27 Few study participants were receiving ART and all had
relatively high CD4 levels, and were therefore not representative of
typical patients. Similarly, data on linezolid in HIV-infected MDR-TB
patients are lacking; fewer than 10% of patients in two recent
systematic reviews were HIV-infected.28,29 This lack of evidence of
the efﬁcacy and safety of new drugs in HIV-infected patients is a
barrier to access. WHO states that ‘special caution’ is required for the
use of bedaquiline in HIV-infected adults.30 In particular, concerns
about potential drug-drug interactions and additive side effects with
ART have resulted in cautious guidance around use of new drugs in
people with HIV,31 and registrations (such for bedaquiline in South
Africa) only for patients not receiving ART.32 Given the burden of
MDR-TB among HIV-infected individuals and the clear beneﬁts of
early initiation of ART with TB treatment, access to new TB drugs for
HIV-infected individuals is required.33
Persons who use alcohol and recreational drugs are also at
increased risk for TB, as well as HIV and hepatitis C, but these
conditions are often an exclusion criterion for participation in
clinical trials. There is little research on new medications in this
population. These individuals commonly have co-morbidities,
making drug-drug interactions a major concern. Substance use (or
opioid substitution therapy) and medications used to treat TB, HIV
and hepatitis C can also have overlapping risk of cardio- and
hepatotoxicity. A better understanding of how MDR-TB can be
safely treated in persons using alcohol and other recreational drugs
is an urgent need, but the exclusion of such persons from research
and program use leaves this population behind.
6. Conclusions
New drugs to treat MDR-TB provide renewed hope for patients
and clinicians. However, access to these drugs is very limited,
particularly in countries with the highest TB burdens and least
resources. This paper presents some signiﬁcant challenges faced by
patients, providers, and programs in accessing new and re-
purposed drugs to effectively treat MDR-TB. Barriers to pre-
approval access can be devastating to individuals suffering from
highly resistant disease, while delays in research, registration and
the provision of technical assistance hinder access in a more
widespread manner. Costs are another signiﬁcant barrier to access,
for both new drugs and repurposed agents, and urgent collective
action is needed to bring the price of these products to an
affordable level for patients and programs. Optimal beneﬁt from
new drugs will require use in combination with existing and
repurposed drugs in new regimens; however, research is lacking
into such combinations. In addition, research is needed to inform
use in key populations such as children and people with HIV.
Overcoming each of these individual barriers will require
speciﬁc solutions. Companies need to design and implement pre-
approval access programs early in the course of drug development,
provide clear guidance and transparent eligibility criteria, and
work with countries to ensure that expedited requests and rapid
shipment can be arranged. Countries need to develop regulatory
and legal frameworks that allow for pre-approval drug use for
patients with MDR-TB. Work to develop normative guidance and
technical assistance around these issues should begin while
awaiting formal WHO guidance and arrival of the new and re-
purposed drugs in country. The TB community must take the lead,
rather than allowing proﬁt-driven companies to decide the ‘‘fair’’
market value of these drugs. Researchers, funders, and regulators
must support innovative research to assess new, shorter and moretolerable drug combinations that include new drugs, and includes
vulnerable groups. Frank and open communication between all
stakeholders with an interest in improving the lives and health of
persons affected by MDR-TB is an essential action step to
effectively address all of these barriers. We hope that sharing
the experiences presented in this paper will continue this dialogue.
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